EUS-guided treatment of gastric fundal varices with combined injection of coils and cyanoacrylate glue: a large U.S. experience over 6 years (with video)

Conventional endoscopic treatment of gastric fundal varices (GFV) with cyanoacrylate (CYA) glue may be complicated by embolization and rebleeding. We evaluated the long-term outcomes of EUS-guided injection of coils and CYA glue for therapy of GFV. A retrospective chart review of patients treated fo...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Gastrointestinal endoscopy Jg. 83; H. 6; S. 1164 - 1172
Hauptverfasser: Bhat, Yasser M., Weilert, Frank, Fredrick, R. Todd, Kane, Steven D., Shah, Janak N., Hamerski, Chris M., Binmoeller, Kenneth F.
Format: Journal Article
Sprache:Englisch
Veröffentlicht: United States Elsevier Inc 01.06.2016
Schlagworte:
Adult
Aged
Aged, 80 and over
Combined Modality Therapy
Cyanoacrylates - therapeutic use
Embolization, Therapeutic - methods
Endosonography
Esophageal and Gastric Varices - therapy
Female
Gastric Fundus
Gastroenterology and Hepatology
Gastrointestinal Hemorrhage - prevention & control
Gastrointestinal Hemorrhage - therapy
Gastroscopy - methods
Hemostasis, Endoscopic
Humans
Male
Middle Aged
Retrospective Studies
Surgery, Computer-Assisted
Surgical Equipment
Tissue Adhesives - therapeutic use
Treatment Outcome
Young Adult
GFV
CYA
TIPS
gastric fundal varices
transjugular intrahepatic portosystemic shunt
cyanoacrylate
ISSN:0016-5107, 1097-6779, 1097-6779
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Conventional endoscopic treatment of gastric fundal varices (GFV) with cyanoacrylate (CYA) glue may be complicated by embolization and rebleeding. We evaluated the long-term outcomes of EUS-guided injection of coils and CYA glue for therapy of GFV. A retrospective chart review of patients treated for GFV was performed. The main outcomes measured were hemostasis, obliteration on surveillance EUS, post-treatment bleeding rate, and adverse events. From March 2009 to 2015, 152 patients with GFV were treated. Seven (5%) had active hemorrhage, 105 (69%) had recent bleeding, and 40 (26%) were treated for primary prophylaxis. Treatment was technically successful in 151 patients (>99%). Mean number of coils was 1.4 (range, 1-4 coils), and mean volume of CYA was 2 mL (range, 0.5-6). Follow-up was available for 125 patients with treated GFV (mean, 436 days; range, 30-2043). Among 100 patients with follow-up EUS examinations, complete obliteration (on Doppler study) of GFV was confirmed in 93 (93%). Post-treatment bleeding from obliterated GFV occurred in 3 of 93 patients (3%). Twenty-five patients who had clinical and/or EGD follow-up had 3 post-treatment bleeding episodes after a median follow-up of 324 days (range, 41-486). Among the 40 patients treated for primary prophylaxis, 28 underwent follow-up EUS and 27 (96%) had confirmed obliteration. Mild postprocedure abdominal pain occurred in 4 of 125 patients (3%), and clinical signs of pulmonary embolization were seen in 1 patient (1%). Another 4 of 125 patients (3%) presented with minor delayed upper GI bleeding from coil/glue extrusion. EUS-guided combined coil and CYA glue injection of high-risk GFV appears to be highly effective for hemostasis in active bleeding and primary and secondary bleeding prophylaxis. Once obliteration was achieved, post-treatment bleeding from GFV occurred in only 3% during long-term follow-up. Combination therapy appears safe and may reduce the risk of CYA embolization.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
ISSN:0016-5107
1097-6779
1097-6779
DOI:10.1016/j.gie.2015.09.040